← Leaderboards
Laura Elisabeth Dichtel
Massachusetts General Hospital
$1,371,693
Attributed
$1,371,693
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $271K · FY2017–23$500K$375K$250K$125K$0
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,371,693 · 2
By mechanism
K23$1,119,693 · 1
R03$252,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Karen K Miller$23,499,917
- Miriam Antoinette Bredella$11,700,851
- Maurizio Fava$41,478,557
- Ralph Weissleder$110,468,710
- Takara Leah Stanley$7,360,441
Others in their field
Other Emerging Leaders on “Knock-Out”
- Jacqueline K White · Jackson Laboratory$12,769,161
- Sonia Minikel Vallabh · Broad Institute, Inc.$8,252,543
- George R Uhl · National Institute On Drug Abuse$6,473,982
- Jennifer M Munson · Virginia Polytechnic Inst And St Univ$6,406,197
- Xiaobo Mao · Johns Hopkins University$6,011,989
- Jurgen Bernd Bulitta · State University Of New York At Buffalo$5,968,993
Research focus
Knock-OutLiverFunctional DisorderIntrahepaticInsulin-Like Growth Factor ILipidsFatty LiverFibrosisGrowth Hormone ReceptorHistologicInflammationComplicationInflammatory MarkerDisease ProgressionCohortFatty Acid Glycerol EstersFda ApprovedCareerAnimal ModelGrowth Hormone DeficiencyHepaticCirrhosisHypopituitarismLiver Diseases
Grant awards (9)
Metabolomic Investigation of the Impact of Growth Hormone on Nonalcoholic Fatty Liver Disease: Identification of Novel Biomarkers and Therapeutic Targets$126,000
R03 · FY2023 · DK · contact PI
Metabolomic Investigation of the Impact of Growth Hormone on Nonalcoholic Fatty Liver Disease: Identification of Novel Biomarkers and Therapeutic Targets$126,000
R03 · FY2022 · DK · contact PI
The Growth Hormone and Insulin-like Growth Factor-1 Axis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis$198,297
K23 · FY2021 · DK · contact PI
The Growth Hormone and Insulin-like Growth Factor-1 Axis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis$72,706
K23 · FY2021 · DK · contact PI
The Growth Hormone and Insulin-like Growth Factor-1 Axis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis$198,297
K23 · FY2020 · DK · contact PI
The Growth Hormone and Insulin-like Growth Factor-1 Axis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis$54,000
K23 · FY2020 · DK · contact PI
The Growth Hormone and Insulin-like Growth Factor-1 Axis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis$198,297
K23 · FY2019 · DK · contact PI
The Growth Hormone and Insulin-like Growth Factor-1 Axis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis$198,297
K23 · FY2018 · DK · contact PI
The Growth Hormone and Insulin-like Growth Factor-1 Axis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis$199,799
K23 · FY2017 · DK · contact PI